



Argos Therapeutics
Investor Relations Department
4233 Technology Drive
Durham, NC 27704
United States

[Visit IR website](#) 
[Sign-up for Email alerts](#) 

NASDAQ: ARG5


| | |
|---------------|----------------------------|
| Last Trade: | 1.36 |
| Trade Time: | 4:00 PM ET Feb 22, 2018 |
| Change: | 0.00 (0.000%) |
| Day Range | 1.34 - 1.50 |
| 52-Week Range | 1.33 - 32.00 |
| Volume | 808,916 |

Stock information is provided by eSignal,
stock charts provided by EDGAR Online.
Stock data is delayed approximately 20
minutes.

Company Profile

Argos Therapeutics is a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases based on its Arcelis™ technology platform. Using biological components from each patient, Arcelis-based immunotherapies employ the patient's dendritic cells to activate an immune response specific to the patient's disease. Argos' most advanced product candidates include AGS-003 for the treatment of metastatic renal cell carcinoma, or mRCC, and AGS-004 for the treatment of HIV. [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

- Feb 15, 2018*
[Argos Announces Issuance of Patent Covering the Foundation for Manufacturing its HIV Immunotherapy](#)
- Feb 5, 2018*
[Argos Obtains Option to License PD1 Checkpoint Inhibitors](#)
- Jan 18, 2018*
[Argos Announces One-for-Twenty Reverse Stock Split](#)
- Jan 8, 2018*
[Argos Announces \\$1.5 Million Equity Investment by Lummy \(Hong Kong\), Ltd.](#)
- Nov 28, 2017*
[Argos Provides Financial Update](#)

Financials [\[View all \]](#)

- Mar 16, 2017*
[Annual Report \(10-K\)](#)
- Jul 6, 2017*
[Proxy Statement \(DEF 14A\)](#)
- Nov 9, 2017*
[Quarterly Report \(10-Q\)](#)
- Aug 9, 2017*
[Quarterly Report \(10-Q\)](#)
- May 10, 2017*
[Quarterly Report \(10-Q\)](#)